Info

Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases with operations in the United States and Europe. The Company’s focus is on diseases caused by hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Prior to October 1, 2007, it developed, commercialized and manufactured telbivudine for the treatment of patients with chronic hepatitis B. Certain of these activities were done with Novartis Pharma AG (Novartis). Telbivudine is marketed as Tyzeka in the United States and Sebivo outside the United States. In April 2007, Sebivo was approved in the European Union for the treatment of patients with chronic hepatitis B. During the year ended December 31, 2007, Tyzeka/Sebivo was approved in more than 50 countries world-wide, including China.(Source: 10-K)